• Lilly's Q4 profit falls on strong dollar, charge Friday, 30 Jan 2015 | 8:06 AM ET
    Bottles of Eli Lilly's Cymbalta on a pharmacy shelf in Princeton, Illinois.

    Eli Lilly has been on a roller-coaster ride in the wake of patent expirations, CEO John Lechleiter tells CNBC.

  • AbbVie profit beats estimates on higher Humira sales Friday, 30 Jan 2015 | 8:04 AM ET

    Jan 30- U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira. The company reported a net loss of $810 million, or 51 cents per share, in the fourth quarter due to a charge from calling off a $55 billion deal to buy British drugmaker Shire Plc. Excluding special items, AbbVie...

  • Activis CEO: Innovation vs. acquisition  Friday, 30 Jan 2015 | 7:45 AM ET

    Brent Saunders, Actavis CEO, discusses how Actavis is leading the way in growth pharma and talks about its M&A strategy.

  • Jan 30- Eli Lilly and Co cut its 2015 revenue forecast, issued earlier this month, as the U.S. drugmaker expects a bigger hit from a stronger dollar. Large U.S. healthcare companies such as Johnson& Johnson, Pfizer Inc and Bristol-Myers Squibb Co have in the past weeks issued 2015 earnings forecasts below Wall Street expectations, citing the stronger dollar.

  • Embracing 'disruptive' technology: Celgene CEO  Friday, 30 Jan 2015 | 7:33 AM ET

    Robert Hugin, Celgene chairman & CEO, discusses his company's efforts to fight cancer and discusses promising drugs in the pipeline.

  • LLY's quarterly checkup: CEO  Friday, 30 Jan 2015 | 7:15 AM ET

    John Lechleiter, Eli Lilly CEO, runs through the quarterly numbers and provides insight to products coming off patents, R&D, and new Alzheimer's drugs in the pipeline.

  • Reinventing pharma's next big frontier: Pro  Friday, 30 Jan 2015 | 7:05 AM ET

    Fred Hassan, Warburg Pincus Partner, talks about the way information technology is changing the face of modern medicine and transforming the health care industry.

  • White House targets precision medicine  Friday, 30 Jan 2015 | 7:03 AM ET

    CNBC's Meg Tirrell has details on the meeting today between President Obama and drugmakers to discuss how to improve health and treat disease.

  • Jan 30- U.S. drugmaker Eli Lilly and Co reported a 41 percent fall in quarterly profit, hurt by a stronger dollar and a one-time charge related to a restructuring program. The U.S. drugmaker said it earned $428.5 million, or 40 cents per share, in the fourth quarter ended Dec. 31 from $727.5 million, or 67 cents per share, a year earlier. The company's earnings have been...

  • Jan 29- Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million. The deal is subject to higher and better bids and extended the bid deadline to Feb. 10 for interested parties to participate in an...

  • Expect measles outbreak to continue: Doctor Thursday, 29 Jan 2015 | 3:37 PM ET
    Mickey Mouse performs during a parade at Disneyland where over 70 people have been infected by a measles outbreak linked to the park.

    Measles is not a disease you should fool with, warned Vanderbilt University's Dr. William Schaffner.

  • Abbott CEO losing no sleep over stronger dollar Thursday, 29 Jan 2015 | 3:15 PM ET

    Jan 29- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics. Half of its sales are in emerging markets, like China and...

  • NEW YORK— Generic drugmaker Mylan said Thursday that its shareholders approved its purchase of an Abbott Laboratories business and its tax-reducing move to the Netherlands. As part of the purchase, Mylan will reorganize in the Netherlands as a company called Mylan NV, reducing its tax expenses. Mylan says Abbott will own 22 percent of Mylan NV but that it won't...

  • Abbott Labs 2015 outlook in line with estimates Thursday, 29 Jan 2015 | 11:05 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Abbott Laboratories forecast full-year profit in line with analysts' estimates even as other drugmakers warned of a strong dollar hurting results.

  • Jan 29- Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results. The company, which received more than 70 percent of revenue from outside the United States, said it expects 2015 earnings of $2.10- $2.20 per share, compared with the average...

  • The rise and rise of life sciences  Thursday, 29 Jan 2015 | 4:55 AM ET

    George Freeman MP, minister of life sciences in the U.K., says there's been a "resurgence" for life sciences and healthcare investment.

  • Cracking down on cat allergies  Thursday, 29 Jan 2015 | 4:30 AM ET

    Steve Harris, CEO of Circassia, says his company is combating allergies by tackling how they affect people's immune systems, rather than simply making products that provide "symptomatic relief".

  • *AstraZeneca working with academic groups and Thermo Fisher. LONDON, Jan 29- AstraZeneca said on Thursday it had struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases. The collaborations with Britain's Wellcome Trust Sanger Institute, the...

  • Salix Pharma to restate past seven quarters' results Wednesday, 28 Jan 2015 | 5:02 PM ET

    Jan 28- Salix Pharmaceuticals Ltd said it will restate its financial statements for all of 2013 and the first three quarters of 2014 due to errors relating to, among others, the timing of revenue recognition. The drugmaker said the cumulative impact of the restatement will decrease reported net product revenue by about $20.7 million and net income by about...

  • Correction: Earns-Amgen story Wednesday, 28 Jan 2015 | 3:37 PM ET

    In a story Jan. 27 about drugmaker Amgen's quarterly results, The Associated Press misspelled the name of a drug and misstated the type of cancer another drug treats. Amgen tops Street 4 Q forecasts. Amgen beats 4 Q net income and revenue expectations.